Ultragenyx Pharmaceutical Q2 EPS $(1.52) Beats $(1.72) Estimate, Sales $147.03M Beat $123.18M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported better-than-expected Q2 results with EPS of $(1.52) beating the $(1.72) estimate and sales of $147.03M surpassing the $123.18M estimate. This marks significant improvements over the same period last year.
August 01, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ultragenyx Pharmaceutical reported Q2 EPS of $(1.52), beating the $(1.72) estimate, and sales of $147.03M, surpassing the $123.18M estimate. This represents significant improvements over the same period last year.
Ultragenyx Pharmaceutical's better-than-expected Q2 earnings and sales figures indicate strong operational performance and positive market reception. The significant improvements over last year's figures suggest a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100